ea0070aep332 | Diabetes, Obesity, Metabolism and Nutrition | ECE2020
Sgro’ Daniele
, Giannarelli Rosa
, Aragona Michele
, Viola Nicola
, Cosentino Giada
, Brancatella Alessandro
, Latrofa Francesco
, Del Prato Stefano
, Santini Ferruccio
, Marcocci Claudio
, Lupi Isabella
Context: Programmed cell death protein 1/programmed cell death protein ligand 1 (PD-1/PD-L1) are key regulators in T-cell activation and tolerance. Nivolumab (PD-1 inhibitor) and Atezolizumab (PD-L1 inhibitor) are monoclonal antibodies approved for the treatment of several types of advanced cancers. Immune checkpoint inhibition caused by these drugs can result in immune-related adverse events (irAEs) New-onset diabetes mellitus has been reported in fewer than 1% of patients an...